Abstract
Depressive disorder is one of the most widespread forms of mental disorders which lead to a significant public health concern, such as disability, suicide, and so on. Its etiology remains vague but it is believed that depressive disorder is a multifactorial disease which is induced by the interaction of social, psychological, and biological factors. Thus, there is no clear and definite pathological theory could illustrate its mechanism independently until now, involving genetics, neuroimaging, neuroinflammation, neuroendocrine, and others. Comprehensive assessment to patients with depression is the starting point for a right diagnosis. History-taking of physical condition is as important as psychiatric interview and rational usage of scales would be beneficial for screening. There are many kinds of therapeutic measures for depressive patients nowadays, including general intervention, pharmacotherapy, psychotherapy, and physical therapy. For now, anti-depressants used in clinical practice is almost monoamine-based drugs while much more progress have been made in developing new antidepressant medications, like prototypical N-methyl-D-aspartate (NMDA) receptor antagonists, opioid agonists, gamma-aminobutyric acid (GABAA) receptors, and psychedelics. Once these novel drugs are proved to be practicable, it will create a historical evolution in the field of psychiatry. In addition, we advocate that measurement-based care (MBC) should run through the whole duration of treatment and goals of MBC in every stage are different. As brain projects in many countries are conducting in inspiring ways, we believe that our understanding about depressive disorder, of course, and other neuropsychiatric disorders will be better in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bartelle BB, Barandov A, Jasanoff A (2016) Molecular fMRI. J Neurosci 36:4139–4148
Battle DE (2013) Diagnostic and statistical manual of mental disorders (DSM). Codas 25:191–192
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
Bi Y, He Y (2014) Connectomics reveals faulty wiring patterns for depressed brain. Biol Psychiatry 76:515–516
Blamire AM (2008) The technology of MRI—the next 10 years? Br J Radiol 81:601–617
Bolton JM, Au W, Chateau D, Walld R, Leslie WD, Enns J, Martens PJ, Katz LY, Logsetty S, Sareen J (2016) Bereavement after sibling death: a population-based longitudinal case-control study. World Psychiatry 15:59–66
Bullmore E, Sporns O (2012) The economy of brain network organization. Nat Rev Neurosci 13:336–349
Burns MN, Begale M, Duffecy J, Gergle D, Karr CJ, Giangrande E, Mohr DC (2011) Harnessing context sensing to develop a mobile intervention for depression. J Med Internet Res 13:e55
Camp JG, Badsha F, Florio M, Kanton S, Gerber T, Wilsch-Brauninger M, Lewitus E, Sykes A, Hevers W, Lancaster M, Knoblich JA, Lachmann R, Paabo S, Huttner WB, Treutlein B (2015) Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci USA 112:15672–15677
Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ, Votaw JR, Goodman MM, Miller AH (2012) Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 69:1044–1053
Chibanda D, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, Munjoma R, Araya R, Weiss HA, Abas M (2016) Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. J Affect Disord 198:50–55
Clarke H, Flint J, Attwood AS, Munafo MR (2010) Association of the 5-HTTLPR genotype and unipolar depression: a meta-analysis. Psychol Med 40:1767–1778
Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, Bilbe G, Hoyer D, Bartfai T (2007) Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry 12:167–189
Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ (2012) Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis. Biol Psychiatry 71:15–21
Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME (1999) The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 60:142–156
Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, Eikermann M, Durham K, Swee MB, Chang T, Dording C, Soskin D, Kelley J, Mischoulon D, Brown EN, Fava M (2017) Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry 51:55–64
Czeh B, Fuchs E, Wiborg O, Simon M (2016) Animal models of major depression and their clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 64:293–310
Dalton VS, Kolshus E, McLoughlin DM (2014) Epigenetics and depression: return of the repressed. J Affect Disord 155:1–12
Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R (2014) Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28:536–544
Ecker JR, Geschwind DH, Kriegstein AR, Ngai J, Osten P, Polioudakis D, Regev A, Sestan N, Wickersham IR, Zeng H (2017) The BRAIN initiative cell census consortium: lessons learned toward generating a comprehensive brain cell atlas. Neuron 96:542–557
Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR (2010) Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 68:748–754
Emerging Risk Factors Collaboration (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140.
Eyre H, Baune BT (2012) Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 37:1397–1416
Feinberg DA, Vu AT, Beckett A (2018) Pushing the limits of ultra-high resolution human brain imaging with SMS-EPI demonstrated for columnar level fMRI. Neuroimage 164:155–163
Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH (2013) Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 31:153–160
Gaska M, Kusmider M, Solich J, Faron-Gorecka A, Krawczyk MJ, Kulakowski K, Dziedzicka-Wasylewska M (2012) Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level. Psychopharmacology 223:281–297
Gautier A, Gauron C, Volovitch M, Bensimon D, Jullien L, Vriz S (2014) How to control proteins with light in living systems. Nat Chem Biol 10:533–541
Golden RN, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB (2005) The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 162:656–662
Gong Q, He Y (2015) Depression, neuroimaging and connectomics: a selective overview. Biol Psychiatry 77:223–235
Grieve SM, Korgaonkar MS, Koslow SH, Gordon E, Williams LM (2013) Widespread reductions in gray matter volume in depression. Neuroimage Clin 3:332–339
Guo T, Xiang YT, Xiao L, Hu CQ, Chiu HF, Ungvari GS, Correll CU, Lai KY, Feng L, Geng Y, Feng Y, Wang G (2015) Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry 172:1004–1013
Hagan CC, Graham JM, Tait R, Widmer B, van Nieuwenhuizen AO, Ooi C, Whitaker KJ, Simas T, Bullmore ET, Lennox BR, Sahakian BJ, Goodyer IM, Suckling J (2015) Adolescents with current major depressive disorder show dissimilar patterns of age-related differences in ACC and thalamus. Neuroimage Clin 7:391–399
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Han KM, Choi S, Jung J, Na KS, Yoon HK, Lee MS, Ham BJ (2014) Cortical thickness, cortical and subcortical volume, and white matter integrity in patients with their first episode of major depression. J Affect Disord 155:42–48
Hollis F, Kabbaj M (2014) Social defeat as an animal model for depression. ILAR J 55:221–232
Hu Y, Hong W, Smith A, Yu S, Li Z, Wang D, Yuan C, Cao L, Wu Z, Huang J, Fralick D, Phillips MR, Fang Y (2017) Association analysis between mitogen-activated protein/extracellular signal-regulated kinase (MEK) gene polymorphisms and depressive disorder in the Han Chinese population. J Affect Disord 222:120–125
Januar V, Saffery R, Ryan J (2015) Epigenetics and depressive disorders: a review of current progress and future directions. Int J Epidemiol 44:1364–1387
Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kulesskaya N, Agustsdottir A, Antila H, Popova D, Akamine Y, Bahi A, Sullivan R, Hen R, Drew LJ, Castren E (2011) Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334:1731–1734
Kiecolt-Glaser JK, Derry HM, Fagundes CP (2015) Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 172:1075–1091
Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381–1391
Kohler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctot KL, Carvalho AF (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135:373–387
Korgaonkar MS, Williams LM, Song YJ, Usherwood T, Grieve SM (2014) Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br J Psychiatry 205:321–328
Korte SM, Prins J, Krajnc AM, Hendriksen H, Oosting RS, Westphal KG, Korte-Bouws GA, Olivier B (2015) The many different faces of major depression: it is time for personalized medicine. Eur J Pharmacol 753:88–104
Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613
Lake BB, Ai R, Kaeser GE, Salathia NS, Yung YC, Liu R, Wildberg A, Gao D, Fung HL, Chen S, Vijayaraghavan R, Wong J, Chen A, Sheng X, Kaper F, Shen R, Ronaghi M, Fan JB, Wang W, Chun J, Zhang K (2016) Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science 352:1586–1590
Liang X, Zou Q, He Y, Yang Y (2013) Coupling of functional connectivity and regional cerebral blood flow reveals a physiological basis for network hubs of the human brain. Proc Natl Acad Sci U S A 110:1929–1934
Lu M, Zhu XH, Chen W (2016) In vivo (31) P MRS assessment of intracellular NAD metabolites and NAD(+)/NADH redox state in human brain at 4 T. NMR Biomed 29:1010–1017
Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter ID, Salvadore G, Zarate CA (2010) The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel) 3:19–41
Major Depressive Disorder Working Group of the Psychiatric (2013) A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 18:497–511
Malykhin NV, Coupland NJ (2015) Hippocampal neuroplasticity in major depressive disorder. Neuroscience 309:200–213
Mao R, Zhang C, Chen J, Zhao G, Zhou R, Wang F, Xu J, Yang T, Su Y, Huang J, Wu Z, Cao L, Wang Y, Hu Y, Yuan C, Yi Z, Hong W, Wang Z, Peng D, Fang Y (2018) Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. J Affect Disord 237:65–72
Mathews A, MacLeod C (2005) Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol 1:167–195
McGuffin P, Cohen S, Knight J (2007) Homing in on depression genes. Am J Psychiatry 164:195–197
Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34
Mohr DC, Burns MN, Schueller SM, Clarke G, Klinkman M (2013) Behavioral intervention technologies: evidence review and recommendations for future research in mental health. Gen Hosp Psychiatry 35:332–338
Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389
Nutt DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69(Suppl E1):4–7
O’Connor E, Rossom RC, Henninger M, Groom HC, Burda BU, Henderson JT, Bigler KD, Whitlock EP (2016) Screening for depression in adults: an updated systematic evidence review for the U.S. preventive services task force, Rockville, MD
Orozco-Solis R, Sassone-Corsi P (2014) Circadian clock: linking epigenetics to aging. Curr Opin Genet Dev 26:66–72
Ota M, Noda T, Sato N, Hattori K, Hori H, Sasayama D, Teraishi T, Nagashima A, Obu S, Higuchi T, Kunugi H (2015) White matter abnormalities in major depressive disorder with melancholic and atypical features: a diffusion tensor imaging study. Psychiatry Clin Neurosci 69:360–368
Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF (2016) Major depressive disorder. Nat Rev Dis Primers 2:16065
Packer AM, Roska B, Hausser M (2013) Targeting neurons and photons for optogenetics. Nat Neurosci 16:805–815
Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N (2013) Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 11:129
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31–41
Rudolf S, Greggersen W, Kahl KG, Huppe M, Schweiger U (2014) Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res 217:34–38
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917
Saeb S, Zhang M, Karr CJ, Schueller SM, Corden ME, Kording KP, Mohr DC (2015) Mobile phone sensor correlates of depressive symptom severity in daily-life behavior: an exploratory study. J Med Internet Res 17:e175
Salgado-Delgado R, Tapia Osorio A, Saderi N, Escobar C (2011) Disruption of circadian rhythms: a crucial factor in the etiology of depression. Depress Res Treat 2011:839743
Sampogna G (2017) ICD-11: draft diagnostic guidelines for mental disorders: a report for WPA membership. Psychiatr Pol 51:397–406
Schatzberg AF (2014) A word to the wise about ketamine. Am J Psychiat 171:262–264
Semenkovich K, Brown ME, Svrakic DM, Lustman PJ (2015) Depression in type 2 diabetes mellitus: prevalence, impact, and treatment. Drugs 75:577–587
Sexton CE, Mackay CE, Ebmeier KP (2009) A systematic review of diffusion tensor imaging studies in affective disorders. Biol Psychiatry 66:814–823
Shadrina M, Bondarenko EA, Slominsky PA (2018) Genetics factors in major depression disease. Front Psychiatry 9:334
Sharp T (2013) Molecular and cellular mechanisms of antidepressant action. Curr Top Behav Neurosci 14:309–325
Sillaber I, Panhuysen M, Henniger MS, Ohl F, Kuhne C, Putz B, Pohl T, Deussing JM, Paez-Pereda M, Holsboer F (2008) Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology 200:557–572
Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173:816–826
Slattery DA, Cryan JF (2014) The ups and downs of modelling mood disorders in rodents. ILAR J 55:297–309
Soria V, Urretavizcaya M (2009) Circadian rhythms and depression. Actas Esp Psiquiatr 37:222–232
Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Hardeland R, Poeggeler B, Cardinali DP (2009) Pathophysiology of depression: role of sleep and the melatonergic system. Psychiatry Res 165:201–214
Stratmann M, Konrad C, Kugel H, Krug A, Schoning S, Ohrmann P, Uhlmann C, Postert C, Suslow T, Heindel W, Arolt V, Kircher T, Dannlowski U (2014) Insular and hippocampal gray matter volume reductions in patients with major depressive disorder. PLoS ONE 9:e102692
Sugimoto K, Kakeda S, Watanabe K, Katsuki A, Ueda I, Igata N, Igata R, Abe O, Yoshimura R, Korogi Y (2018) Relationship between white matter integrity and serum inflammatory cytokine levels in drug-naive patients with major depressive disorder: diffusion tensor imaging study using tract-based spatial statistics. Transl Psychiatry 8:141
Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 157:1552–1562
Tomasi D, Wang GJ, Volkow ND (2013) Energetic cost of brain functional connectivity. Proc Natl Acad Sci U S A 110:13642–13647
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, Team SDS (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40
Wang Z, Dai Z, Gong G, Zhou C, He Y (2015) Understanding structural-functional relationships in the human brain: a large-scale network perspective. Neuroscientist 21:290–305
Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262–9267
Williams NR, Schatzberg AF (2016) NMDA antagonist treatment of depression. Curr Opin Neurobiol 36:112–117
World Health Organization (1992) International statistical classificationof diseases and related health problems. 10th Revision (ICD-10). World Health Organization, Geneva
Zhang C, Zhang DF, Wu ZG, Peng DH, Chen J, Ni J, Tang W, Xu L, Yao YG, Fang YR (2016) Complement factor H and susceptibility to major depressive disorder in Han Chinese. Br J Psychiatry 208:446–452
Zhao D, Wu Z, Zhang H, Mellor D, Ding L, Wu H, Wu C, Huang J, Hong W, Peng D, Fang Y (2018) Somatic symptoms vary in major depressive disorder in China. Compr Psychiatry 87:32–37
Zhou R, Wang F, Zhao G, Xia W, Peng D, Mao R, Xu J, Wang Z, Hong W, Zhang C, Wang Y, Su Y, Huang J, Yang T, Wang J, Chen J, Palaniyappan L, Fang Y (2018) Effects of tumor necrosis factor-alpha polymorphism on the brain structural changes of the patients with major depressive disorder. Transl Psychiatry 8:217
Zuithoff NP, Vergouwe Y, King M, Nazareth I, van Wezep MJ, Moons KG, Geerlings MI (2010) The Patient Health Questionnaire-9 for detection of major depressive disorder in primary care: consequences of current thresholds in a crosssectional study. BMC Fam Pract 11:98
Zung WW, Richards CB, Short MJ (1965) Self-rating depression scale in an outpatient clinic: further validation of the SDS. Arch Gen Psychiatry 13:508–515
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Fang, Y., Mao, R. (2019). Introduction. In: Fang, Y. (eds) Depressive Disorders: Mechanisms, Measurement and Management. Advances in Experimental Medicine and Biology, vol 1180. Springer, Singapore. https://doi.org/10.1007/978-981-32-9271-0_1
Download citation
DOI: https://doi.org/10.1007/978-981-32-9271-0_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9270-3
Online ISBN: 978-981-32-9271-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)